Cover Image
市場調查報告書

Seroquel XR(重度憂鬱症)-預測與市場分析

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305483
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Seroquel XR(重度憂鬱症)-預測與市場分析 Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 45 Pages
簡介

重度憂鬱症(MDD)是世界最常見的精神疾病之一。其市場競爭激烈,有超過30個產品上市中,在Eli Lilly的Cymbalta、大塚製薬/BMS的Abilify等主力產品專利即將到期,及Lundbeck/武田薬品工業的Brintellix等位於最終階段平台產品即將上市的當下,市場正在大大變化中。當初AstraZeneca是為了治療精神分裂症及燥鬱症所開發的,並未獲得MDD治療藥之認証。在Seroquel XR開發下,從2009年依序成為美國、澳洲、EU5個國家的MDD指定輔助治療藥。

本報告提供重度憂鬱症的治療藥物Seroquel XR之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等彙整資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀及亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 症狀和治療概要

第5章 競爭評估

  • 概要

第6章 Seroquel XR (Quetiapine)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC424DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Seroquel XR (quetiapine) (extended-release tablets) is an atypical antipsychotic that is indicated as an adjunctive treatment for MDD in the US, 5EU, and Australia. AstraZeneca initially developed the Seroquel immediate release formulation for the treatment of schizophrenia and bipolar disorder, but has not gained regulatory approvals for MDD with Seroquel. With the development of Seroquel XR, AstraZeneca expanded the label of this product for the treatment of MDD as an adjunctive therapy, initially in 2009 in the US and Australia, followed by an approval in 2010 in the 5EU.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Seroquel XR including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Seroquel XR for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Seroquel XR performance
  • Obtain sales forecast for Seroquel XR from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Seroquel XR (Quetiapine)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed MDD Patients
    • 7.4.2. Percent of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Directors
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Product Profile - Seroquel XR
  • Table 8: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants
  • Table 9: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events
  • Table 10: Seroquel XR SWOT Analysis, 2014
  • Table 11: Global MDD Sales Forecasts ($m) for Seroquel XR, 2013-2023
  • Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
Back to Top